trending Market Intelligence /marketintelligence/en/news-insights/trending/4MtvUa2gfCkp2-FWjVkkOg2 content esgSubNav
In This List

Depomed to lose some revenue as a result of Hurricane Maria

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Depomed to lose some revenue as a result of Hurricane Maria

Depomed Inc. said it would lose about $2 million to $3 million in third-quarter Nucynta-related revenues as a result of damage caused by Hurricane Maria.

The opioid painkiller is produced in Puerto Rico by a third-party manufacturing partner. According to the most recent assessment, the facility that produces the drug sustained minor damage, and site leaders are working to return the facility to full operation.

The company expects a further negative impact of less than $10 million in fourth-quarter Nucynta revenues as a result of the ongoing disruption to manufacturing operations.

The disruption will not impact the supply of Gralise, which is also produced in Puerto Rico.

Nucynta generated $281.2 million in revenue during the full year ended Dec. 31, 2016. For the six months ended June 30, 2017, the drug generated $124.6 million in sales.